Abstract | BACKGROUND: METHODS: RESULTS: The mean baseline IOP was 19.82 ± 1.19 mmHg in the test eyes and 18.32 ± 1.11 mmHg in the control eyes. The mean IOP at the one-month visit was 18.23 ± 1.17 mmHg in the test eyes and 18.45 ± 1.04 mmHg in the control eyes. The test eyes demonstrated a decrease in IOP of 1.59 (± 0.95) mmHg from the baseline, or a 6.82 per cent decrease in the IOP from the baseline. The control eyes had an increase in IOP of 0.14 ± 0.77 mmHg from the baseline, or a 1.91 per cent increase in the IOP. The relative difference in the IOP between the test eyes and the control eyes at the one-month visit was 1.73 mmHg, or 8.74 per cent. CONCLUSION:
|
Authors | Dominick L Opitz, Sherman Tung, Unsun Sarah Jang, Jenny J Park |
Journal | Clinical & experimental optometry
(Clin Exp Optom)
Vol. 94
Issue 5
Pg. 438-42
(Sep 2011)
ISSN: 1444-0938 [Electronic] United States |
PMID | 21342261
(Publication Type: Journal Article)
|
Copyright | © 2011 The Authors. Clinical and Experimental Optometry © 2011 Optometrists Association Australia. |
Chemical References |
- Antihypertensive Agents
- Silicones
- Cloprostenol
- Travoprost
|
Topics |
- Adult
- Antihypertensive Agents
(therapeutic use)
- Cloprostenol
(analogs & derivatives, therapeutic use)
- Combined Modality Therapy
(methods)
- Female
- Glaucoma, Open-Angle
(drug therapy, surgery)
- Humans
- Intraocular Pressure
(drug effects)
- Male
- Ocular Hypertension
(drug therapy, surgery)
- Prostheses and Implants
- Prosthesis Implantation
- Silicones
(therapeutic use)
- Travoprost
|